Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.66 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293443 | 1.00 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15812979 | 0.88 | PIK3CB (0.58) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15812980 | 0.88 | PIK3CB (0.58) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15813150 | 0.84 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15813151 | 0.84 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15812491 | 0.84 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15812490 | 0.84 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15812935 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15812937 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA | |
| SCHEMBL15815291 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3R1PIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008053-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3008053-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| CN-105308034-B | Phosphatidylinositol 3-kinase inhibitors | 吉利德科学公司 | 2017-10-31 | — | — | CN | disclosed |
| US-20160039793-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| CN-105308034-A | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES INC | 2016-02-03 | — | — | CN | disclosed |
| US-9221795-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039793-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R4, PIK3R5 | PIK3CD 4/4885PIK3R1 5/4885PIK3CB 11/4885 |
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R4, PIK3R5 | PIK3CD 4/4885PIK3R1 5/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.